Geoffrey L Uy

List of Publications by Year
in descending order

226 papers	9,299 citations	66343 42 h-index	45317 90 g-index
226 all docs	226 docs citations	226 times ranked	10691 citing authors

#	Article	IF	Citations
1	Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML. New England Journal of Medicine, 2018, 378, 2386-2398.	27.0	1,092
2	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 2684-2692.	1.6	682
3	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
4	Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 2009, 113, 6206-6214.	1.4	456
5	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, 119, 3917-3924.	1.4	347
6	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1045-1056.	2.0	319
7	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood, 2020, 135, 463-471.	1.4	266
8	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
9	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021, 137, 751-762.	1.4	183
10	Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene, 2001, 20, 1839-1851.	5.9	181
11	Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. New England Journal of Medicine, 2021, 384, 924-935.	27.0	170
12	BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood, 2009, 114, 1340-1343.	1.4	153
13	Targeting CD123 in acute myeloid leukemia using a T-cellâ€“directed dual-affinity retargeting platform. Blood, 2016, 127, 122-131.	1.4	148
14	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 1761-1769.	2.0	143
15	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances, 2016, 1, 250-259.	5.2	142
16	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation, 2016, 22, 1851-1860.	2.0	135
17	Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.. Journal of Clinical Oncology, 2016, 34, 7000-7000.	1.6	130
18	Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279.	4.9	116

#	Article	IF	Citations
19	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood, 2011, 117, 1828-1833.	1.4	104
20	Plerixafor. Nature Reviews Drug Discovery, 2009, 8, 105-107.	46.4	97
21	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
22	Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opinion on Biological Therapy, 2008, 8, 1797-1804.	3.1	92
23	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1646-1652.	2.0	92
24	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematology,the, 2021, 8, e481-e491.	4.6	92
25	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Journal of Clinical Investigation, 2011, 121, 1445-1455.	8.2	91
26	Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia, 2017, 31, 872-881.	7.2	87
27	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2014, 20, 46-52.	2.0	86
28	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871.	9.4	83
29	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia, 2019, 33, 2599-2609.	7.2	76
30	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transplant Infectious Disease, 2017, 19, e12629.	1.7	75
31	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433.	6.4	72
32	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733.	2.0	71
33	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680.	5.2	71
34	Targeting the Microenvironment in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2015, 10, 126-131.	2.3	68
35	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102.	4.9	67
36	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood, 2017, 129, 2680-2692.	1.4	66

#	Article	IF	Citations
37	Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 417-425.	2.3	64
38	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 2017, 1, 331-340.	5.2	57
39	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia, 2019, 33, 1620-1634.	7.2	55
40	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica, 2016, 101, e465-e468.	3.5	54
41	A phase II study of 5â€day intravenous azacitidine in patients with myelodysplastic syndromes. American Journal of Hematology, 2009, 84, 560-564.	4.1	51
42	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific DartÂ® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2017, 130, 637-637.	1.4	49
43	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375.	12.4	49
44	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	4.1	45
45	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advances, 2020, 4, 696-705.	5.2	44
46	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 414-423.	4.9	44
47	Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential Gâ€CSF. American Journal of Hematology, 2009, 84, 733-737.	4.1	42
48	A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer Journal, 2017, 7, e542-e542.	6.2	41
49	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood, 2022, 139, 1177-1183.	1.4	41
50	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1072-1077.	2.0	39
51	A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia, 2013, 27, 725-728.	7.2	38
52	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653.	2.0	38
53	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). Journal of Geriatric Oncology, 2020, 11, 107-113.	1.0	38
54	Chemotherapy versus Hypomethylating Agents forÂtheÂTreatment of Relapsed Acute Myeloid Leukemia andÂMyelodysplastic Syndrome after Allogeneic StemÂCellÂTransplant. Biology of Blood and Marrow Transplantation, 2016, 22, 1324-1329.	2.0	35

#	Article	IF	Citations
55	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2015, 50, 1513-1518.	2.4	34
56	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
57	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
58	Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, 587-589.	1.4	32
59	Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. International Journal of Hematology, 2014, 99, 272-278.	1.6	32
60	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. Leukemia Research, 2016, 49, 1-6.	0.8	31
61	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). Blood, 2014, 124, 8-8.	1.4	31
62	Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. Blood, 2018, 132, 561-561.	1.4	30
63	Dual Receptor T Cells Mediate Pathologic Alloreactivity in Patients with Acute Graft-Versus-Host Disease. Science Translational Medicine, 2013, 5, 188ra74.	12.4	29
64	Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Advances, 2020, 4, 239-251.	5.2	29
65	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 2017, 102, 1391-1400.	3.5	28
66	Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. Blood, 2016, 128, 1070-1070.	1.4	28
67	Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia, 2010, 24, 1662-1664.	7.2	27
68	Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood, 2019, 134, 15-15.	1.4	27
69	Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplantation, 2009, 43, 793-800.	2.4	26
70	A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood Advances, 2018, 2, 1295-1299.	5.2	25
71	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplantation, 2014, 49, 1124-1126.	2.4	24
72	Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood, 2017, 129, 1397-1401.	1.4	24

#	Article	IF	Citations
73	Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
74	Oral valganciclovir versus ganciclovir as delayed preâ€emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04â€0274) and review of the literature. Transplant Infectious Disease, 2012, 14, 259-267.	1.7	23
75	Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplantation, 2015, 50, 1057-1062.	2.4	23
76	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10â€day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821.	2.8	21
77	BLâ€8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An openâ€label safety and efficacy phase 2a study. Cancer, 2021, 127, 1246-1259.	4.1	21
78	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood Advances, 2021, 5, 1474-1482.	5.2	20
79	Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplantation, 2009, 44, 13-17.	2.4	19
80	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2017, 23, 2065-2069.	2.0	19
81	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
82	Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001). Blood, 2015, 126, 319-319.	1.4	18
83	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. Blood, 2019, 134, 232-232.	1.4	17
84	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica, 2020, 105, e404-e407.	3.5	16
85	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. Blood, 2011, 118, 82-82.	1.4	16
86	Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.. Journal of Clinical Oncology, 2020, 38, 7510-7510.	1.6	16
87	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 2018, 9, 4354-4365.	1.8	16
88	Expression and Function of PML-RARA in the Hematopoietic Progenitor Cells of Ctsg-PML-RARA Mice. PLoS ONE, 2012, 7, e46529.	2.5	15
89	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology, 2014, 89, E103-8.	4.1	15
90	The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood, 2015, 126, 2546-2546.	1.4	15

#	Article	IF	Citations
91	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 728-730.	1.3	14
92	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E49-E52.	4.1	14
93	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701. Blood, 2018, 132, 309-309.	1.4	14
94	Flotetuzumab, an Investigational CD123 x CD3 Bispecific DartÂ® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. Blood, 2019, 134, 733-733.	1.4	14
95	Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTsÂ®). Blood, 2013, 122, 360-360.	1.4	14
96	Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study. Blood, 2017, 130, 725-725.	1.4	14
97	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal of Hematology, 2021, 113, 92-99.	1.6	13
98	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Advances, 2021, 5, 1719-1728.	5.2	13
99	Exhaled nitric oxide correlates with experimental lung transplant rejection. Annals of Thoracic Surgery, 2000, 69, 210-215.	1.3	12
100	Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia and Lymphoma, 2009, 50, 14-23.	1.3	12
101	A protease-resistant PML-RARÎ± has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood, 2010, 116, 3604-3610.	1.4	12
102	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430.	2.0	12
103	Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation. Thorax, 2018, 73, 489-492.	5.6	12
104	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6524-6531.	7.0	12
105	CD123 bi-specific antibodies in development in AML: What do we know so far?. Best Practice and Research in Clinical Haematology, 2020, 33, 101219.	1.7	12
106	Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO Oncology Practice, 2020, 16, e464-e475.	2.9	12
107	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. Blood, 2020, 136, 16-18.	1.4	12
108	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. Blood, 2015, 126, 796-796.	1.4	12

#	Article	IF	Citations
109	Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leukemia Research, 2015, 39, 1437-1442.	0.8	11
110	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 2535-2540.	1.3	11
111	CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leukemia and Lymphoma, 2019, 60, 2287-2290.	1.3	11
112	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.2	11
113	A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 1156-1165.	2.6	11
114	Machine learningâ€“based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Advances, 2022, 6, 1991-2000.	5.2	11
115	Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational New Drugs, 2020, 38, 1430-1441.	2.6	10
116	Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia, 2021, 35, 3278-3281.	7.2	10
117	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. Blood, 2010, 116, 1060-1060.	1.4	10
118	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica, 2022, 107, 770-773.	3.5	10
119	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 568-583.	3.8	10
120	Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. American Journal of Hematology, 2014, 89, 487-492.	4.1	9
121	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances, 2021, 5, 4691-4700.	5.2	9
122	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713.	0.8	9
123	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific DartÂ® Molecule for T-Cell Redirected Therapy. Blood, 2018, 132, 2738-2738.	1.4	9
124	Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2018, 132, 89-89.	1.4	9
125	Plasmacytoma-Like Post-Transplantation Lymphoproliferative Disease Occurring in a Cardiac Allograft: A Case Report and Review of the Literature. Journal of Clinical Oncology, 2012, 30, e278-e282.	1.6	8
126	Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study. Blood, 2018, 132, 1425-1425.	1.4	8

#	Article	IF	Citations
127	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. Blood, 2007, 110, 916-916.	1.4	8
128	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. Blood, 2008, 112, 1944-1944.	1.4	8
129	A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance). Blood, 2016, 128, 2782-2782.	1.4	7
130	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. Blood, 2017, 130, 816-816.	1.4	7
131	Transplant outcomes after CPX-351 vs 7â€‰+â€‰3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Advances, 2022, 6, 4989-4993.	5.2	7
132	A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2014, 49, 1366-1370.	2.4	6
133	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e588-e593.	0.4	6
134	Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7â€‰+â€‰3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Hematology and Oncology, 2021, 14, 110.	17.0	6
135	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. Blood, 2019, 134, 3915-3915.	1.4	6
136	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colonyâ€“Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Biology of Blood and Marrow Transplantation, 2017, 23, 1282-1289.	2.0	5
137	Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2019, 134, 2547-2547.	1.4	5
138	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. Blood, 2020, 136, 19-21.	1.4	5
139	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML. Blood, 2020, 136, 44-45.	1.4	5
140	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. Blood, 2009, 114, 787-787.	1.4	5
141	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood, 2015, 126, 1950-1950.	1.4	5
142	Development of XpertÂ® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale. Blood, 2015, 126, 2793-2793.	1.4	5
143	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 2022, 107, 1034-1044.	3.5	4
144	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4

#	Article	IF	Citations
145	CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma. Blood, 2019, 134, 2630-2630.	1.4	4
146	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific DartÂ® Molecule for T-Cell Redirected Therapy. Blood, 2019, 134, 5144-5144.	1.4	4
147	Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.. Blood, 2007, 110, 867-867.	1.4	4
148	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. Blood, 2009, 114, 842-842.	1.4	4
149	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. Blood, 2014, 124, 1931-1931.	1.4	4
150	Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614). Blood, 2018, 132, 1386-1386.	1.4	4
151	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
152	Choosing induction chemotherapy in therapy-related acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 89-97.	1.7	3
153	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. Blood, 2020, 136, 46-48.	1.4	3
154	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). Blood, 2013, 122, 2653-2653.	1.4	3
155	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. Blood, 2013, 122, 5492-5492.	1.4	3
156	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. Blood, 2015, 126, 610-610.	1.4	3
157	The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. Blood, 2016, 128, 2745-2745.	1.4	3
158	Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.. Journal of Clinical Oncology, 2018, 36, 7000-7000.	1.6	3
159	CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.. Journal of Clinical Oncology, 2018, 36, 7027-7027.	1.6	3
160	The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models. Blood, 2018, 132, 2700-2700.	1.4	3
161	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2021, 62, 1441-1449.	1.3	2
162	Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy. Blood, 2019, 134, 1366-1366.	1.4	2

#	Article	IF	Citations
163	Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood, 2020, 136, 55-56.	1.4	2
164	Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, TPS7567-TPS7567.	1.6	2
165	Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).. Journal of Clinical Oncology, 2018, 36, 7031-7031.	1.6	2
166	Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. Blood, 2018, 132, 118-118.	1.4	2
167	Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Haematologica, 2022, 107, 1709-1713.	3.5	2
168	The effect of donor type on outcomes in adults with acute myeloid leukemia after reducedâ€intensity hematopoietic peripheral blood cell transplant â€“ a retrospective study. Transplant International, 2020, 33, 1089-1098.	1.6	1
169	The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML. Blood, 2018, 132, 2706-2706.	1.4	1
170	FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. Blood, 2007, 110, 1855-1855.	1.4	1
171	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3417-3417.	1.4	1
172	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. Blood, 2010, 116, 1063-1063.	1.4	1
173	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. Blood, 2010, 116, 823-823.	1.4	1
174	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. Blood, 2014, 124, 2447-2447.	1.4	1
175	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 2557-2557.	1.4	1
176	A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome. Blood, 2015, 126, 1686-1686.	1.4	1
177	CD34+-Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 3098-3098.	1.4	1
178	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
179	Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients â‰¥ 60 years old. Journal of Clinical Oncology, 2008, 26, 7058-7058.	1.6	1
180	Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).. Journal of Clinical Oncology, 2020, 38, 7521-7521.	1.6	1

#	Article	IF	Citations
181	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. Blood, 2007, 110, 1451-1451.	1.4	1
182	Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.. Blood, 2007, 110, 1203-1203.	1.4	1
183	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. Blood, 2011, 118, 3616-3616.	1.4	1
184	Predicting Autologous Stem Cell Mobilization Failure In Hematologic Malignancies. Blood, 2013, 122, 2034-2034.	1.4	1
185	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456.	1.4	1
186	Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation. Blood, 2014, 124, 906-906.	1.4	1
187	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. Blood, 2019, 134, 2650-2650.	1.4	1
188	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). Blood, 2019, 134, 1247-1247.	1.4	1
189	CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death. Blood, 2019, 134, 2745-2745.	1.4	1
190	Combined Inhibition of CXCR4 Signaling and System xc- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis. Blood, 2020, 136, 37-37.	1.4	1
191	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123Ã—CD3 Bispecific DartÂ® Molecule, in Acute Myeloid Leukemia. Blood, 2020, 136, 26-28.	1.4	1
192	Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.. Journal of Clinical Oncology, 2022, 40, 7031-7031.	1.6	1
193	Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. Oncology Reviews, 2009, 3, 59-70.	1.8	0
194	All I Really Need to Know I Learned From Pediatric Oncologists. JCO Oncology Practice, 2020, 16, 239-240.	2.9	0
195	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) >10,000 Copies/Ml or >5,000 Copies/Ml X 2. Blood, 2008, 112, 4340-4340.	1.4	0
196	A Protease-Resistant PML-RARÎ± Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL).. Blood, 2008, 112, 930-930.	1.4	0
197	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. Blood, 2008, 112, 4427-4427.	1.4	0
198	Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. Blood, 2009, 114, 3335-3335.	1.4	0

#	Article	IF	Citations
199	Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,. Blood, 2011, 118, 3633-3633.	1.4	0
200	Phase I Study of Cladribine (2-chlorodeoxyadenosie), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. Blood, 2011, 118, 3609-3609.	1.4	0
201	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931.	1.4	0
202	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
203	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1398-1398.	1.4	0
204	CXCR4/CXCL12 as a Therapeutic Target. , 2015, , 607-615.		0
205	G-CSF Augments Inotuzamab-Mediated Clearance of Acute Lymphoblastic Leukemia from the Bone Marrow. Blood, 2014, 124, 5502-5502.	1.4	0
206	Impact of Remission Status on Outcomes in AML Patients â‰¥ 60 Years of Age after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1263-1263.	1.4	0
207	Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. Blood, 2014, 124, 3944-3944.	1.4	0
208	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. Blood, 2014, 124, 5292-5292.	1.4	0
209	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850.	1.4	0
210	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144.	1.4	0
211	Clinical Evaluation of XpertÂ® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1. Blood, 2015, 126, 5170-5170.	1.4	0
212	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. Blood, 2015, 126, 3106-3106.	1.4	0
213	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. Blood, 2016, 128, 4658-4658.	1.4	0
214	Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology, 2018, 36, 7040-7040.	1.6	0
215	Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Blood, 2018, 132, 2170-2170.	1.4	0
216	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0

#	Article	IF	Citations
217	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). Blood, 2018, 132, 2767-2767.	1.4	0
218	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2019, 134, 2694-2694.	1.4	0
219	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. Blood, 2021, 138, 800-800.	1.4	0
220	Medical Simulation in High-Risk AML Improves Clinical Decision Making of Hematologists/Oncologists. Blood, 2021, 138, 4985-4985.	1.4	0
221	Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results. Blood, 2021, 138, 2316-2316.	1.4	0
222	Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance). Blood, 2021, 138, 1983-1983.	1.4	0
223	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. Blood, 2021, 138, 3904-3904.	1.4	0
224	TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. Blood, 2020, 136, 3-4.	1.4	0
225	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). Blood, 2020, 136, 30-31.	1.4	0
226	Turning AML targets inside out. Blood, 2021, 138, 2598-2599.	1.4	0